Trial Profile
The Effect of Previous Pneumococcal Immunization on the Immune Response of Adult Patients With Severe Chronic Kidney Disease to Prevnar 13
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Jun 2022
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- 20 Jun 2022 Results assessing Opsonophagocytic activity against Streptococcus pneumoniae in Indigenous and non-Indigenous patients with severe chronic kidney disease published in the Vaccine
- 01 Sep 2021 Status changed from active, no longer recruiting to completed.
- 24 Dec 2020 Results published in the Vaccine